Atara Biotherapeutics (NASDAQ:ATRA) Cut to Hold at RODMAN&RENSHAW

RODMAN&RENSHAW lowered shares of Atara Biotherapeutics (NASDAQ:ATRA) from a strong-buy rating to a hold rating in a research report report published on Tuesday,Zacks.com reports.

Several other equities analysts have also issued reports on ATRA. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Wednesday. Rodman & Renshaw assumed coverage on shares of Atara Biotherapeutics in a research report on Friday, December 20th. They set a “buy” rating and a $25.00 target price on the stock. Finally, Canaccord Genuity Group dropped their price target on shares of Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, January 17th. One research analyst has rated the stock with a sell rating, three have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $17.75.

Atara Biotherapeutics Stock Up 0.6 %

Shares of NASDAQ ATRA opened at $6.93 on Tuesday. Atara Biotherapeutics has a 12 month low of $5.40 and a 12 month high of $39.50. The company has a market cap of $39.92 million, a P/E ratio of -0.27 and a beta of 0.51. The business’s 50 day moving average is $12.16 and its two-hundred day moving average is $9.97.

Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, beating the consensus estimate of ($3.77) by $0.84. The company had revenue of $40.19 million for the quarter, compared to analyst estimates of $23.00 million. During the same quarter in the previous year, the company earned ($16.50) earnings per share. Sell-side analysts expect that Atara Biotherapeutics will post -9.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Atara Biotherapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Atara Biotherapeutics in the second quarter valued at approximately $53,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Atara Biotherapeutics in the second quarter valued at $79,000. State Street Corp raised its holdings in shares of Atara Biotherapeutics by 52.3% in the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after buying an additional 7,680 shares during the last quarter. FMR LLC grew its holdings in Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 7,381 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Atara Biotherapeutics by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after acquiring an additional 4,043 shares in the last quarter. 70.90% of the stock is owned by institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.